GleamWall
中文EN

CADL Candel Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1841387 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-335.6%
TTM EPS YoY-173.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-93.6%
ROA-65.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets37.7%
Debt / equity0.00x
Current ratio7.57x
Interest coverage-13.30x

Cash quality & payout

Operating cash flow / net income0.70x
Accruals ratio-19.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$15.59M$19.80M$9.84M$11.03M$8.46M$6.99M$4.02M$4.82M
SG&A expense$7.39M$6.95M$6.44M$4.72M$4.75M$4.19M$4.11M$3.32M
Operating income-$22.98M-$26.75M-$16.28M-$15.75M-$13.21M-$11.18M-$8.13M-$8.14M
Interest expense$1.59M$1.57M$1.56M$1.42M$161,000$236,000$306,000-$3.79M
Net income-$21.87M-$38.91M-$8.86M-$29.50M-$11.27M-$4.80M$7.38M-$14.07M
EBITDA-$22.78M-$26.55M-$16.14M-$15.59M-$13.01M-$10.98M-$7.88M-$7.90M
EPS (basic)-0.28-0.52-0.14—-0.21-0.090.15—
EPS (diluted)-0.28-0.52-0.14—-0.21-0.090.13—
Weighted avg. shares (diluted)77.39M74.13M62.36M—54.89M51.49M54.77M—
Balance sheet
Cash & equivalents$203.12M$201.56M$194.83M$119.73M$87.23M$100.95M$92.43M$102.92M
Current assets$207.35M$204.16M$197.75M$121.39M$90.13M$103.61M$93.15M$103.80M
PP&E, net$1.90M$2.00M$2.08M$1.64M$1.36M$1.66M$1.97M$2.19M
Total assets$211.11M$208.15M$201.92M$125.19M$93.60M$105.97M$95.91M$106.87M
Current liabilities$27.39M$12.69M$7.05M$9.00M$10.93M$14.71M$20.07M$37.53M
Short-term debt———$0$4.22M$6.70M$9.17M$9.89M
Long-term debt———————$1.73M
Total debt———————$11.63M
Total liabilities$79.52M$82.02M$63.89M$73.27M$13.47M$15.76M$21.23M$40.54M
Shareholders' equity$131.59M$126.13M$138.03M$51.92M$80.12M$90.21M$74.67M$66.33M
Net debt———————-$91.29M
Shares outstanding78.45M76.12M73.26M54.90M54.90M54.89M49.25M46.81M
Cash flow statement
Operating cash flow-$23.12M-$17.18M-$18.04M-$10.57M-$10.24M-$8.89M-$8.62M-$5.81M
Capital expenditure$141,000$69,000$675,000$409,000$144,000$31,000$3,000$3,000
Free cash flow-$23.26M-$17.25M-$18.71M-$10.98M-$10.38M-$8.92M-$8.62M-$5.82M
Investing cash flow-$141,000-$69,000-$675,000-$409,000-$117,000-$31,000-$3,000-$3,000
Financing cash flow$24.81M$23.98M$93.81M$43.90M-$3.37M$17.44M-$1.87M$91.91M
Depreciation & amortization$200,000$200,000$149,000$163,000$200,000$200,000$245,000$245,000
Stock-based compensation$2.65M$2.86M$1.45M$1.29M$1.16M$1.05M$314,000$1.24M

Free plan shows the latest 8 periods; Pro shows all 26 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.